Loading...

VNDA VANDA PHARMACEUTICALS INC Legal Disputes 8-K Filing

VND

VND

VANDA PHARMACEUTICALS INC

(VNDA)

2026 8-K

Earnings Call Update

Board Appointment

Executive Resignation

FDA Approval News

FDA Approval Announcement

Executive Compensation Update

Earnings Announcement

FDA Re-Review Result

FDA Approval Granted

FDA Approval Update

Regulatory Update

Earnings Update

FDA Collaboration Reached

Financial Statements

Financial Statements

FDA Application Update

Executive Compensation

Earnings Results

New Drug Application

Earnings Announcement

Acquisition Proposal

Bylaw Amendments

Tradipitant Update

Amendment to Rights Agreement

Rejection of Acquisition Pr...

Acquisition Proposal

Indication of Interest

Rejection of Acquisition Pr...

Management Changes

Annual Meeting of Stockholders

Acquisition Proposal

Dividend Distribution

FDA Response Letter

Compensation Committee Awar...

Amendment to Form 8-K/A

FDA Update on Insomnia Trea...

Bylaws Amendment

Acquisition of PONVORY Rights

Denial of Rehearing

Annual Meeting Voting Results

Appointment of Director

Regulation FD Disclosure

Compensation Committee Awar...

External Links:

On January 7, 2026, Vanda Pharmaceuticals was informed by the FDA that it cannot approve their sNDA for HETLIOZ® as currently submitted. This filing follows a collaborative framework established with the FDA for expedited re-review, previously announced on October 1, 2025.

AI Assistant

VANDA PHARMACEUTICALS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.